Yesterday, the U.S. Department of Health and Human Services finalized a rule expanding short-term, limited-duration insurance plans -- threatening access to adequate, affordable coverage for people with cystic fibrosis who rely on the individual marketplace.
On Friday, a federal judge issued a decision in Texas v. United States, finding the Affordable Care Act to be unconstitutional. This decision could ultimately leave people with pre-existing conditions, like cystic fibrosis, without patient protections while also jeopardizing access to adequate, affordable health care coverage.
The Cystic Fibrosis Foundation has followed the health care reform discussion closely. While the Foundation has not taken a position on any particular health reform bill, we have consistently and aggressively encouraged officials to include specific reforms that are important for the treatment of cystic fibrosis.
The U.S. House of Representatives has passed the American Health Care Act (AHCA), legislation that fails to adequately protect people living with cystic fibrosis.
The draft bill, crafted by the Senate Health, Education, Labor, and Pensions (HELP) Committee, aims to bring stability to the health insurance marketplaces.
Today, the U.S. Senate released its version of the health care reform bill, titled the Better Care Reconciliation Act, and in response, the Cystic Fibrosis Foundation affirmed its opposition to the legislation.
This week, Congress approved a budget resolution that will allow lawmakers to make certain changes to the Affordable Care Act and Medicaid.
As part of the Cystic Fibrosis Foundation's ninth annual Teen Advocacy Day, 162 advocates from 38 states met with elected officials in Washington, D.C., to tell their stories and make sure the cystic fibrosis community is heard in ongoing health care reform discussions.
President Donald Trump signed an executive order on health care that could weaken patient protections. He also announced a plan to stop paying cost-sharing reduction (CSR) subsidies to health insurance companies. Both decisions could negatively affect people with cystic fibrosis.